Elżbieta Nowakowska

Learn More
Schizophrenia manifests itself primarily with positive symptoms, negative symptoms and cognitive disorders. Animal models of mental diseases seem to be an important tool in understanding key theories related with pathophysiology of the disorder and are used to assess efficacy of new drugs. References describe four basic groups of animal models of(More)
The development of tolerance to the pharmacodynamic effects of azopirone (buspirone) and imidazopyridines (alpidem and zolpidem) was investigated. It was found that tolerance to the anxiolytic effect of buspirone develops only after 42 days of administration (twice daily). Of the imidazopyridines alpidem showed an anxiolytic activity, while after zolpidem(More)
Alcoholism is a mental disease in the course of which depression, anxiety, and cognitive function deficits may appear, and these symptoms can be aggravated by comorbid schizophrenia.The aim of this study was to find whether spatial memory (Morris Water Maze) function impairment is found in prenatally stressed rats (PSG) (prenatal stress paradigm - animal(More)
Risperidone is a dopaminergic as well as a 5-HT2 antagonist. The drug was found to exert beneficial effects on both positive and negative symptoms of schizophrenia. Since recently, schizophrenia is regarded as a composite of not only positive and negative but also affective and cognitive symptoms, in this study the effects of risperidone compared with(More)
Brain-derived neurotrophic factor (BDNF) is a key neurotrophic factor in the brain. It plays an important role in the etiopathogenesis and pharmacotherapy of mental disorders, such as depression or schizophrenia. In recent years, studies have shown that cognitive processes, which are impaired in the course of mental disorders, significantly change BDNF(More)
The behavioural effects of two antidepressants with opposite molecular mechanisms, tianeptine 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin - 11-yl)amino]heptanoic acid S,S-dioxide, CAS 66981-73-5) 5 mg/kg p.o., a serotonin reuptake enhancer, and fluoxetine (+/-)-N-methyl-3-phenyl-3-[(alpha, alpha, alpha-trifluoro-p- tolyl)oxy]propylamine,(More)
The aim of this study has been to investigate the effects of vasopressin and oxytocin on antidepressive and memory improving effects of venlafaxine. Male Wistar rats weighing 180-200 g were used in the study. Venlafaxine (20 mg/kg) was administered po 30 min before the test once, and for 7 and 14 days in the chronic experiments. Oxytocin (1 microg/kg) ip(More)
The experiments outlined in this paper examined the effects of the novel antidepressant venlafaxine (VEN) (CAS 9930-78-4) in several behavioural and memory tests in comparison with the classic antidepressant imipramine (IMI) (CAS 113-52-0). The tests were carried out on male Wistar rats of about 200 g. The drugs were administered orally 30 min before the(More)
The aim of our investigations was to supplement the scarce information about behavioral effects of olanzapine and especially to find out if the effects change during prolonged treatment. It was established that at a dose of 0.5 mg/kg, which did not evoke sedation, olanzapine had distinct anxiolytic effects, both after acute and chronic treatment. Olanzapine(More)
The aim of the study was to find whether spatial memory impairment and disruption in locomotor activity were found in prenatally stressed rats (PSG) or prenatally methylazoxymethanol acetate-treated rats (MAMG). In addition to this, we examined basal plasma corticosterone level as well as brain-derived neurothropic factor (BDNF) in the PSG and MAMG rats.(More)